Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 2/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.54 |
| ▸ | LCK | P06239 | 4/20 | 0.54 |
| ▸ | KDR | P35968 | 4/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | MET | P08581 | 2/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | BTK | Q06187 | 2/20 | 0.54 |
| ▸ | FYN | P06241 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | PAK4 | O96013 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356020 | 0.86 | TBK1 (0.74) | TBK1PTK2LCKKDRJAK2 | |
| SCHEMBL1353760 | 0.78 | EGFR (0.65) | TBK1KDRFGFR1AURKAPDGFRB | |
| SCHEMBL1355771 | 0.76 | EIF2AK4 (0.64) | TBK1PTK2LCKKDRJAK2 | |
| SCHEMBL1355147 | 0.76 | TBK1 (0.61) | TBK1PTK2LCKKDRJAK2 | |
| SCHEMBL1356682 | 0.74 | EIF2AK4 (0.61) | TBK1PTK2LCKKDRJAK2 | |
| SCHEMBL4036384 | 0.73 | FLT3 (0.60) | TBK1KDRAURKAFLT3BRD4 | |
| SCHEMBL1356307 | 0.72 | EIF2AK4 (0.61) | TBK1PTK2LCKKDRJAK2 | |
| SCHEMBL1355858 | 0.72 | EIF2AK4 (0.61) | TBK1PTK2LCKKDRJAK2 | |
| SCHEMBL21941982 | 0.72 | EHMT2 (0.62) | TBK1PTK2LCKKDRFGFR1 | |
| SCHEMBL1353635 | 0.71 | EIF2AK4 (0.66) | TBK1PTK2FGFR1FLT3CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308240-A1 | Targeting Innate Immune Signaling in Neuroinflammation and Neurodegeneration | THE GENERAL HOSPITAL CORPORATION | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308240-A1 | Targeting Innate Immune Signaling in Neuroinflammation and Neurodegeneration | TBK1, STAT1, IRF3 | TBK1 1/4885PTK2 1084/4885LCK 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.